


A network map of Interleukin-10 signaling pathway

Renu Verma^{1,2} · Lavanya Balakrishnan¹ · Kusum Sharma³ · Aafaque Ahmad Khan^{1,2} · Jayshree Advani^{1,4} · Harsha Gowda^{1,12} · Srikanth Prasad Tripathy⁵ · Mrutyunjay Suar² · Akhilesh Pandey^{6,7,8,9} · Sheetal Gandotra¹⁰ · T. S. Keshava Prasad^{1,11,12} · Subramanian Shankar¹³ 

Received: 7 July 2015 / Accepted: 24 July 2015 / Published online: 8 August 2015
© The International CCN Society 2015

Abstract Interleukin-10 (IL-10) is an anti-inflammatory cytokine with important immunoregulatory functions. It is primarily secreted by antigen-presenting cells such as activated T-cells, monocytes, B-cells and macrophages. In biologically functional form, it exists as a homodimer that binds to tetrameric heterodimer IL-10 receptor and induces downstream

signaling. IL-10 is associated with survival, proliferation and anti-apoptotic activities of various cancers such as Burkitt lymphoma, non-Hodgkins lymphoma and non-small cell lung cancer. In addition, it plays a central role in survival and persistence of intracellular pathogens such as *Leishmania donovani*, *Mycobacterium tuberculosis* and

✉ T. S. Keshava Prasad
keshav@ibioinformatics.org

✉ Subramanian Shankar
shankarsid@gmail.com

Renu Verma
renuverma@ibioinformatics.org

Lavanya Balakrishnan
lavanya@ibioinformatics.org

Kusum Sharma
sharmakusum9@yahoo.co.in

Aafaque Ahmad Khan
aafaque@ibioinformatics.org

Jayshree Advani
jayshree@ibioinformatics.org

Harsha Gowda
harsha@ibioinformatics.org

Srikanth Prasad Tripathy
directorjalma@gmail.com

Mrutyunjay Suar
msbiotek@yahoo.com

Akhilesh Pandey
pandey@jhmi.edu

Sheetal Gandotra
sheetal.gandotra@igib.in

¹ International Technology Park, Whitefield,, Institute of Bioinformatics, Bangalore 560 066, India

² School of Biotechnology, KIIT University, Bhubaneswar, Odisha 751 024, India

³ Department of Medical Microbiology, Post Graduate Institute of Medical Education and Research, Chandigarh 160 012, India

⁴ Manipal University, Madhav Nagar, Manipal 576 104, India

⁵ Department of Microbiology, National JALMA Institute for Leprosy & Other Mycobacterial Diseases (Indian Council of Medical Research), Agra 282 004, India

⁶ McKusick-Nathans Institute of Genetic Medicine, Baltimore, MD, USA

⁷ Departments of Biological Chemistry, Johns Hopkins University School of Medicine, 733N. Broadway, Baltimore, MD 21205, USA

⁸ Departments of Oncology, Johns Hopkins University School of Medicine, 733N. Broadway, Baltimore, MD 21205, USA

⁹ Departments of Pathology, Johns Hopkins University School of Medicine, 733N. Broadway, Baltimore, MD 21205, USA

¹⁰ CSIR-Institute of Genomics and Integrative Biology, New Delhi 110 020, India

¹¹ NIMHANS-IOB Proteomics and Bioinformatics Laboratory, Neurobiology Research Centre, National Institute of Mental Health and Neurosciences, Bangalore 560029, India

¹² YU-IOB Center for Systems Biology and Molecular Medicine, Yenepoya University, Mangalore 575018, India

¹³ Command Hospital (Air Force), Bangalore 560 007, India

Trypanosoma cruzi inside the host. The signaling mechanisms of IL-10 cytokine are not well explored and a well annotated pathway map has been lacking. To this end, we developed a pathway resource by manually annotating the IL-10 induced signaling molecules derived from literature. The reactions were categorized under molecular associations, activation/inhibition, catalysis, transport and gene regulation. In all, 37 molecules and 76 reactions were annotated. The IL-10 signaling pathway can be freely accessed through NetPath, a resource of signal transduction pathways previously developed by our group.

Keywords Co-stimulatory molecules · Interferon-gamma (IFN- γ) · Lipopolysaccharides · Pro-inflammatory cytokines · Protein-protein interactions · Translocation · NetSlim · Systems biology markup language

Abbreviations

IL-10	Interleukin-10
CSIF	Cytokine synthesis inhibitory factor
PPIs	Protein-protein interactions
PTMs	Post-translational modifications
BioPAX	Biological PATHway eXchange
SBML	Systems biology markup language
PSI-MI	Proteomics standards initiative for molecular interaction
HPRD	Human protein reference database

Introduction

Interleukin-10 (IL-10), also known as ‘cytokine synthesis inhibitory factor’ (CSIF), is a pleiotropic cytokine with important immunoregulatory functions. It has anti-inflammatory properties and influences the activity of several cell types of the immune system. IL-10 is primarily secreted by activated T-cells, monocytes, macrophages, dendritic cells, natural killer (NK) cells and B-cells (Blanco et al. 2008; Seki et al. 1998; Chomarat et al. 1993). It is released upon activation of these cells by endogenous and exogenous mediators such as lipopolysaccharides (Barsig et al. 1995; Roach et al. 1995), catecholamines and cAMP-elevating drugs (Meisel et al. 1996; Jilg et al. 1996). In response to antigens, cells of the immune system produce pro-inflammatory cytokines such as tumor necrosis factor alpha (TNF- α), interferon -gamma (IFN- γ), interleukin-2 (IL-2) and interleukin-1 (IL-1) (de Waal et al. 1991). They are involved in rapid pathogen clearance and cell necrosis at the site of infection. Prolonged action of pro-inflammatory cytokines can lead to excessive tissue damage, fever, inflammation, and death in extreme cases (Dinarello 2000). IL-10 dampens the inflammatory effects of pro-inflammatory cytokines in overwhelming infections which

otherwise can lead to potential tissue damage (Kapur et al. 1997; Wang et al. 1994; Cassatella et al. 1993).

The human *IL10* gene is 4.7 kb in size and is located on the long arm of chromosome 1. It contains five exons. Biologically functional IL-10 exists in the form of a 36 kD homodimer composed of two non-covalently bonded monomers each with 160 amino acids length (Zdanov 2010). Two disulfide bridges exist between the monomers, which are required for their biological activity and maintaining structural integrity (Windsor et al. 1993). IL-10 homodimer binds to tetrameric IL-10 receptor complex, which consists of two IL-10R-alpha and two IL-10R-beta subunits. IL-10R-alpha is known to bind to the ligand and IL-10R-beta is the accessory signaling subunit (Liu et al. 1994).

IL-10 homodimer upon binding to its receptor IL-10R-alpha, activates JAK/STAT (Janus kinase/signal transducer and activator of transcription) and Akt (also known as protein kinase B, PKB) cascades (Riley et al. 1999). IL-10 has also been involved in proliferation, survival and anti-apoptotic activities of several cancers such as Burkitt lymphoma (Kube et al. 1995), non-Hodgkins lymphoma (Cortes and Kurzrock 1997) and non-small cell lung cancer (De Vita et al. 2000b). Studies have reported that overexpression of IL-10 promotes tumor development in certain lymphomas and melanomas by suppressing the antitumor immune response (Huang et al. 1999; Boulland et al. 1998; Kruger-Krasagakes et al. 1994). Several investigations have also suggested that serum level of IL-10 may indicate disease progression. A study in advanced solid tumors has reported that IL-10 serum level returns to normal in radically resected patients. However, in case of tumor recurrence, the IL-10 level was observed to be persistently elevated (De Vita et al. 2000a). Additionally, elevated serum level of IL-10 has also been associated with autoimmune and inflammatory diseases such as systemic lupus erythematosus (SLE) (Park et al. 1998), systemic sclerosis (Hasegawa et al. 1997) and Bullous pemphigoid (Schmidt et al. 1996). Studies have reported a protective role of IL-10 in cartilage of osteoarthritis patients (Jung et al. 2013). Recombinant human IL-10 has also been tested as a promising therapeutic agent in patients with rheumatoid arthritis (Keystone et al. 1998) and Crohn’s disease (Tilg et al. 2002).

IL-10 plays a central role in survival and persistence of intracellular pathogens in vivo. Pathogens such as *Leishmania donovani* (Chandra and Naik 2008; Ghalib et al. 1993) *Mycobacterium tuberculosis* (Higgins et al. 2009), *Trypanosoma cruzi* (Holscher et al. 2000) and *Coxiella burnetii* (Ghigo et al. 2001) have evolved various mechanisms for stimulating IL-10 production in immune cells for their survival. Recent studies have indicated the correlation between IL-10 and tuberculosis (TB) susceptibility in humans and mice (Jamil et al. 2007; Bonceni-Almeida et al. 2004; Olobo et al. 2001; Verbon et al. 1999). IL-10 mediated deactivation of macrophages leads to reduced production of pro-

inhibition reactions corresponding to IL-10 signaling. Information such as cell lines used in experiment and experimental conditions were also documented. In case of post-translational modification (PTM), information on site and residue for PTMs were also curated. Comments on each reaction were written in brief, describing the experiment and results from which the reaction was inferred. An internal review system was followed to confirm the annotation and to avoid any error of commission. In addition, each pathway reaction was reviewed by a Pathway Authority, who has a proven expertise in the field of study (SG, co-author in this article).

IL-10 pathway map generation and visualization

The signaling events derived from manual curation are available as pathway map. We have also developed a pathway map based on the reactions by following NetSlim criteria (Raju et al. 2011b). This enabled us to shortlist high confidence reactions and develop a more stringent IL-10 pathway map. The reactions associated with IL-10 pathway can be visualized using PathVisio (van Iersel et al. 2008). The IL-10 pathway in NetSlim version can be downloaded in png, gpml and pdf formats. The pathway molecules are linked to corresponding NetPath page containing links for ‘Pathway Authority,’ ‘Curator’s details’ and ‘Comments’ section.

Results and discussion

Over 3,000 research articles were screened from PubMed and Google Scholar for curation of molecules associated with IL-10 signalling. Articles identified with the information pertaining to signalling events induced upon binding of IL-10 to its receptor were considered for curation. By manual curation, we curated 04 protein-protein interactions, 30 catalytic reactions, 87 gene regulation events, 04 activation/inhibition events and 01 protein translocation event. These pathway reactions were depicted as signalling network (Fig. 1). The reactions in the map are linked to their respective articles as listed in PubMed. The molecules are linked to their respective pages in NetPath and HPRD (Prasad et al. 2009) and the transcriptionally regulated genes are linked to their corresponding gene pages in NCBI. The data is presented in widely accepted standard formats, namely, Systems Biology Markup Language (SBML 2.1) (Hucka et al. 2003), Proteomics Standard Initiative-Molecular Interaction (PSIMI version 2.5) (Orchard and Kerrien 2010) and Biological Pathways Exchange (BioPAX level 3.0) (Demir et al. 2010). IL-10 pathway page in NetPath gives a brief description on pathway and its importance. A table is provided with pathway statistics on the NetPath page.

Overall, the pathway map depicts that immune cells upon pro-inflammatory cytokine stimulation secrete IL-10, which binds to the extracellular domain of IL-10R-alpha that leads to phosphorylation of JAK1 (Janus Kinase1) associated with IL-10R-alpha and TYK2 (tyrosine kinase2) associated with IL-10R beta (Kotenko et al. 1997). These kinases further phosphorylate tyrosine residues (Y446 and Y496) located on the intracellular domain of IL-10R-Alpha. Phosphorylated residues act as temporary docking sites for STAT3 (Signal Transducer and Activator of Transcription-3) (Donnelly et al. 1999). JAK1 further phosphorylates STAT3, which then homo/hetero dimerize and translocate into the nucleus. In the nucleus, it regulates various cell cycle progression genes such as *BCL2* (Santner-Nanan et al. 2013; Levy and Brouet 1994) along with other anti-apoptotic genes (Donnelly et al. 1999). In addition, it also upregulates v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog B (*MAFB*) which is involved in regulation of macrophage deactivation (Gemelli et al. 2014). IL-10 controls the inflammatory processes by suppressing pro-inflammatory cytokines such as tumor necrosis factor alpha (*TNF*) (van der Poll et al. 1994), interleukin-6 (*IL6*) (Wang et al. 1994) and interleukin-8 (*IL8*) (de Waal et al. 1991). Recently, it has been shown that IL-10 prevents the differentiation of monocytes into dendritic cells, which are one of the important antigen presenting cells of immune system (Buelens et al. 1997). Studies have also reported that IL-10 down regulates co-stimulatory molecules such as *CD86* (Chang et al. 1995) and intracellular adhesion molecule-1 (*ICAM1*) (Spittler et al. 1995) rendering the cells incapable of presenting antigens on their surface. Recent reports have demonstrated that IL-10 induces the expression of heme oxygenase-1 (*HMOX1*) in macrophages, which is a potent anti-inflammatory agent (Koch et al. 2009; Lee and Chau 2002). Secretion of matrix metalloproteinases (*MMP1* and *MMP3*) is also enhanced under the influence of IL-10 (Reitamo et al. 1994). In addition, IL-10 stimulates chondrocytes proliferations and chondrogenic differentiation by activating (Bone Morphogenetic Protein) BMP signalling pathway through phosphorylation of SMAD1, SMAD5 and SMAD9 proteins (Jung et al. 2013).

IL-10 signaling pathway data can be used as a useful resource for understanding the complex mechanisms associated with the anti-inflammatory cytokines. The pathway map developed will also aid in understanding the mechanisms adopted by intracellular pathogens and cancerous cells to combat the immune system and establish their survival in the body. The users can further provide their comments about the pathway in NetPath through (<http://www.netpath.org/comments>).

Acknowledgments We thank the Department of Biotechnology (DBT), Government of India for research support to the Institute of Bioinformatics. We thank the Infosys Foundation for research support

to the Institute of Bioinformatics. RV is a recipient of a Junior Research Fellowship from the University Grants Commission (UGC), Government of India. AAK is a recipient of Senior Research Fellowship from Indian Council of Medical Research (ICMR), Government of India. JA is a recipient of Senior Research Fellowship from Council of Scientific & Industrial Research (CSIR), Government of India. TSKP is the recipient of the DST-IDP research grant (IDP/MED/2011/23-general) on “Development of epitope based diagnostic gadget for detection of *Mycobacterium tuberculosis* in the Indian population” from the Department of Science Technology, Government of India. HG is a Wellcome Trust/DBT India Alliance Early Career Fellow. SG is a Wellcome Trust/DBT India Alliance Intermediate Fellow.

Conflict of interests The author(s) declare that they have no competing interests.

References

- Barsig J, Kusters S, Vogt K, Volk HD, Tiegs G, Wendel A (1995) Lipopolysaccharide-induced interleukin-10 in mice: role of endogenous tumor necrosis factor- α . *Eur J Immunol* 25:2888–2893
- Blanco P, Palucka AK, Pascual V, Banchereau J (2008) Dendritic cells and cytokines in human inflammatory and autoimmune diseases. *Cytokine Growth Factor Rev* 19:41–52
- Bonecini-Almeida MG, Ho JL, Boechat N, Huard RC, Chitale S, Doo H, Geng J, Rego L, Lazzarini LC, Kritski AL, Johnson WD Jr, McCaffrey TA, Silva JR (2004) Down-modulation of lung immune responses by interleukin-10 and transforming growth factor beta (TGF- β) and analysis of TGF- β receptors I and II in active tuberculosis. *Infect Immun* 72:2628–2634
- Boulland ML, Meignin V, Leroy-Viard K, Copie-Bergman C, Briere J, Touitou R, Kanavaros P, Gaulard P (1998) Human interleukin-10 expression in T/natural killer-cell lymphomas: association with anaplastic large cell lymphomas and nasal natural killer-cell lymphomas. *Am J Pathol* 153:1229–1237
- Buelens C, Verhasselt V, De Groote D, Thielemans K, Goldman M, Willems F (1997) Interleukin-10 prevents the generation of dendritic cells from human peripheral blood mononuclear cells cultured with interleukin-4 and granulocyte/macrophage-colony-stimulating factor. *Eur J Immunol* 27:756–762
- Cassatella MA, Meda L, Bonora S, Ceska M, Constantin G (1993) Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1 β in mediating the production of IL-8 triggered by lipopolysaccharide. *J Exp Med* 178:2207–2211
- Chandra D, Naik S (2008) Leishmania donovani infection down-regulates TLR2-stimulated IL-12p40 and activates IL-10 in cells of macrophage/monocytic lineage by modulating MAPK pathways through a contact-dependent mechanism. *Clin Exp Immunol* 154:224–234
- Chang Q, Hanks S, Akard L, Thompson J, Harvey K, English D, Jansen J (1995) Maturation of mobilized peripheral blood progenitor cells: preclinical and phase I clinical studies. *J Hematother* 4:289–297
- Chomarat P, Risoan MC, Banchereau J, Miossec P (1993) Interferon gamma inhibits interleukin 10 production by monocytes. *J Exp Med* 177:523–527
- Cortes J, Kurzrock R (1997) Interleukin-10 in non-Hodgkin's lymphoma. *Leuk Lymphoma* 26:251–259
- de la Barrera S, Aleman M, Musella R, Schierloh P, Pasquinelli V, Garcia V, Abbate E, Sasiain Mdel C (2004) IL-10 down-regulates costimulatory molecules on *Mycobacterium tuberculosis*-pulsed macrophages and impairs the lytic activity of CD4 and CD8 CTL in tuberculosis patients. *Clin Exp Immunol* 138:128–138
- De Vita F, Orditura M, Galizia G, Romano C, Lieto E, Iodice P, Tuccillo C, Catalano G (2000a) Serum interleukin-10 is an independent prognostic factor in advanced solid tumors. *Oncol Rep* 7:357–361
- De Vita F, Orditura M, Galizia G, Romano C, Roscigno A, Lieto E, Catalano G (2000b) Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. *Chest* 117:365–373
- de Waal MR, Abrams J, Bennett B, Figdor CG, de Vries JE (1991) Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. *J Exp Med* 174:1209–1220
- Demir E, Cary MP, Paley S, Fukuda K, Lemer C, Vastrik I, Wu G, D'Eustachio P, Schaefer C, Luciano J, Schacherer F, Martinez-Flores I, Hu Z, Jimenez-Jacinto V, Joshi-Tope G, Kandasamy K, Lopez-Fuentes AC, Mi H, Pichler E, Rodchenkov I, Splendiani A, Tkachev S, Zucker J, Gopinath G, Rajasimha H, Ramakrishnan R, Shah I, Syed M, Anwar N, Babur O, Blinov M, Brauner E, Corwin D, Donaldson S, Gibbons F, Goldberg R, Hornbeck P, Luna A, Murray-Rust P, Neumann E, Ruebenacker O, Samwald M, van Iersel M, Wimalaratne S, Allen K, Braun B, Whirl-Carrillo M, Cheung KH, Dahlquist K, Finney A, Gillespie M, Glass E, Gong L, Haw R, Honig M, Hubaut O, Kane D, Krupa S, Kutmon M, Leonard J, Marks D, Merberg D, Petri V, Pico A, Ravenscroft D, Ren L, Shah N, Sunshine M, Tang R, Whaley R, Letovksy S, Buetow KH, Rzhetsky A, Schachter V, Sobral BS, Dogrusoz U, McWeeney S, Aladjem M, Birney E, Collado-Vides J, Goto S, Hucka M, Le Novere N, Maltsev N, Pandey A, Thomas P, Wingender E, Karp PD, Sander C, Bader GD (2010) The BioPAX community standard for pathway data sharing. *Nat Biotechnol* 28:935–942
- Dinarello CA (2000) Proinflammatory cytokines. *Chest* 118:503–508
- Donnelly RP, Dickensheets H, Finbloom DS (1999) The interleukin-10 signal transduction pathway and regulation of gene expression in mononuclear phagocytes. *J Interferon Cytokine Res* 19:563–573
- Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A (1991) IL-10 inhibits cytokine production by activated macrophages. *J Immunol* 147:3815–3822
- Gemelli C, Zanocco Marani T, Biccato S, Mazza EM, Boraschi D, Salsi V, Zappavigna V, Parenti S, Selmi T, Tagliafico E, Ferrari S, Grande A (2014) MafB is a downstream target of the IL-10/STAT3 signaling pathway, involved in the regulation of macrophage de-activation. *Biochim Biophys Acta* 1843:955–964
- Ghalib HW, Piuvezam MR, Skeiky YA, Siddig M, Hashim FA, el-Hassan AM, Russo DM, Reed SG (1993) Interleukin 10 production correlates with pathology in human Leishmania donovani infections. *J Clin Invest* 92:324–329
- Ghigo E, Capo C, Raoult D, Mege JL (2001) Interleukin-10 stimulates *Coxiella burnetii* replication in human monocytes through tumor necrosis factor down-modulation: role in microbicidal defect of Q fever. *Infect Immun* 69:2345–2352
- Gong JH, Zhang M, Modlin RL, Linsley PS, Iyer D, Lin Y, Barnes PF (1996) Interleukin-10 downregulates *Mycobacterium tuberculosis*-induced Th1 responses and CTLA-4 expression. *Infect Immun* 64:913–918
- Hasegawa M, Fujimoto M, Kikuchi K, Takehara K (1997) Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. *J Rheumatol* 24:328–332
- Higgins DM, Sanchez-Campillo J, Rosas-Taraco AG, Lee EJ, Orme IM, Gonzalez-Juarrero M (2009) Lack of IL-10 alters inflammatory and immune responses during pulmonary *Mycobacterium tuberculosis* infection. *Tuberculosis (Edinb)* 89:149–157
- Holscher C, Mohrs M, Dai WJ, Kohler G, Ryffel B, Schaub GA, Mossmann H, Brombacher F (2000) Tumor necrosis factor alpha-

- mediated toxic shock in *Trypanosoma cruzi*-infected interleukin 10-deficient mice. *Infect Immun* 68:4075–4083
- Huang S, Ullrich SE, Bar-Eli M (1999) Regulation of tumor growth and metastasis by interleukin-10: the melanoma experience. *J Interferon Cytokine Res* 19:697–703
- Hucka M, Finney A, Sauro HM, Bolouri H, Doyle JC, Kitano H, Arkin AP, Bornstein BJ, Bray D, Cornish-Bowden A, Cuellar AA, Dronov S, Gilles ED, Ginkel M, Gor V, Goryanin II, Hedley WJ, Hodgman TC, Hofmeyr JH, Hunter PJ, Juty NS, Kasberger JL, Kremling A, Kummer U, Le Novere N, Loew LM, Lucio D, Mendes P, Minch E, Mjolsness ED, Nakayama Y, Nelson MR, Nielsen PF, Sakurada T, Schaff JC, Shapiro BE, Shimizu TS, Spence HD, Stelling J, Takahashi K, Tomita M, Wagner J, Wang J (2003) The systems biology markup language (SBML): a medium for representation and exchange of biochemical network models. *Bioinformatics* 19:524–531
- Jamil B, Shahid F, Hasan Z, Nasir N, Razzaki T, Dawood G, Hussain R (2007) Interferon gamma/IL10 ratio defines the disease severity in pulmonary and extra pulmonary tuberculosis. *Tuberculosis (Edinb)* 87:279–287
- Jilg S, Barsig J, Leist M, Kusters S, Volk HD, Wendel A (1996) Enhanced release of interleukin-10 and soluble tumor necrosis factor receptors as novel principles of methylxanthine action in murine models of endotoxic shock. *J Pharmacol Exp Ther* 278:421–431
- Jung YK, Kim GW, Park HR, Lee EJ, Choi JY, Beier F, Han SW (2013) Role of interleukin-10 in endochondral bone formation in mice: anabolic effect via the bone morphogenetic protein/Smad pathway. *Arthritis Rheum* 65:3153–3164
- Kandasamy K, Keerthikumar S, Raju R, Keshava Prasad TS, Ramachandra YL, Mohan S, Pandey A (2009) PathBuilder—open source software for annotating and developing pathway resources. *Bioinformatics* 25:2860–2862
- Kandasamy K, Mohan SS, Raju R, Keerthikumar S, Kumar GS, Venugopal AK, Telikicherla D, Navarro JD, Mathivanan S, Pecquet C, Gollapudi SK, Tattikota SG, Mohan S, Padhukasahasram H, Subbannayya Y, Goel R, Jacob HK, Zhong J, Sekhar R, Nanjappa V, Balakrishnan L, Subbaiah R, Ramachandra YL, Rahiman BA, Prasad TS, Lin JX, Houtman JC, Desiderio S, Renauld JC, Constantinescu SN, Ohara O, Hirano T, Kubo M, Singh S, Khatri P, Draghici S, Bader GD, Sander C, Leonard WJ, Pandey A (2010) NetPath: a public resource of curated signal transduction pathways. *Genome Biol* 11:R3
- Kapur S, Jones C, DaSilva J, Wilson A, Houle S (1997) Reliability of a simple non-invasive method for the evaluation of 5-HT2 receptors using [¹⁸F]-setoperone PET imaging. *Nucl Med Commun* 18:395–399
- Keystone E, Wherry J, Grint P (1998) IL-10 as a therapeutic strategy in the treatment of rheumatoid arthritis. *Rheum Dis Clin N Am* 24:629–639
- Koch N, Jung M, Sabat R, Kratzschmar J, Docke WD, Asadullah K, Volk HD, Grutz G (2009) IL-10 protects monocytes and macrophages from complement-mediated lysis. *J Leukoc Biol* 86:155–166
- Kotenko SV, Krause CD, Izotova LS, Pollack BP, Wu W, Pestka S (1997) Identification and functional characterization of a second chain of the interleukin-10 receptor complex. *EMBO J* 16:5894–5903
- Kruger-Krasagakes S, Krasagakis K, Garbe C, Schmitt E, Huls C, Blankenstein T, Diamantstein T (1994) Expression of interleukin 10 in human melanoma. *Br J Cancer* 70:1182–1185
- Kube D, Platzer C, von Knethen A, Straub H, Bohlen H, Hafner M, Tesch H (1995) Isolation of the human interleukin 10 promoter. Characterization of the promoter activity in Burkitt's lymphoma cell lines. *Cytokine* 7:1–7
- Lee TS, Chau LY (2002) Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice. *Nat Med* 8:240–246
- Levy Y, Brouet JC (1994) Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein. *J Clin Invest* 93:424–428
- Liu Y, Wei SH, Ho AS, de Waal MR, Moore KW (1994) Expression cloning and characterization of a human IL-10 receptor. *J Immunol* 152:1821–1829
- Meisel C, Vogt K, Platzer C, Randow F, Liebenthal C, Volk HD (1996) Differential regulation of monocytic tumor necrosis factor-alpha and interleukin-10 expression. *Eur J Immunol* 26:1580–1586
- Olobo JO, Geletu M, Demissie A, Egualé T, Hiwot K, Aderaye G, Britton S (2001) Circulating TNF-alpha, TGF-beta, and IL-10 in tuberculosis patients and healthy contacts. *Scand J Immunol* 53:85–91
- Orchard S, Kerrien S (2010) Molecular interactions and data standardisation. *Methods Mol Biol* 604:309–318
- Park YB, Lee SK, Kim DS, Lee J, Lee CH, Song CH (1998) Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. *Clin Exp Rheumatol* 16:283–288
- Prasad TS, Kandasamy K, Pandey A (2009) Human protein reference database and human proteinpedia as discovery tools for systems biology. *Methods Mol Biol* 577:67–79
- Raju R, Balakrishnan L, Nanjappa V, Bhattacharjee M, Getnet D, Muthusamy B, Kurian Thomas J, Sharma J, Rahiman BA, Harsha HC, Shankar S, Prasad TS, Mohan SS, Bader GD, Wani MR, Pandey A (2011a) A comprehensive manually curated reaction map of RANKL/RANK-signaling pathway. *Database (Oxford)* 2011:bar021
- Raju R, Nanjappa V, Balakrishnan L, Radhakrishnan A, Thomas JK, Sharma J, Tian M, Palapetta SM, Subbannayya T, Sekhar NR, Muthusamy B, Goel R, Subbannayya Y, Telikicherla D, Bhattacharjee M, Pinto SM, Syed N, Srikanth MS, Sathe GJ, Ahmad S, Chavan SN, Kumar GS, Marimuthu A, Prasad TS, Harsha HC, Rahiman BA, Ohara O, Bader GD, Sujatha Mohan S, Schiemann WP, Pandey A (2011b) NetSlim: high-confidence curated signaling maps. *Database (Oxford)* 2011:bar032
- Reitamo S, Remitz A, Tamai K, Uitto J (1994) Interleukin-10 modulates type I collagen and matrix metalloproteinase gene expression in cultured human skin fibroblasts. *J Clin Invest* 94:2489–2492
- Riley JK, Takeda K, Akira S, Schreiber RD (1999) Interleukin-10 receptor signaling through the JAK-STAT pathway. Requirement for two distinct receptor-derived signals for anti-inflammatory action. *J Biol Chem* 274:16513–16521
- Roach TI, Barton CH, Chatterjee D, Liew FY, Blackwell JM (1995) Opposing effects of interferon-gamma on iNOS and interleukin-10 expression in lipopolysaccharide- and mycobacterial lipoarabinomannan-stimulated macrophages. *Immunology* 85:106–113
- Santner-Nanan B, Straubinger K, Hsu P, Parnell G, Tang B, Xu B, Makris A, Hennessy A, Peek MJ, Busch DH, da Costa CP, Nanan R (2013) Fetal-maternal alignment of regulatory T cells correlates with IL-10 and Bcl-2 upregulation in pregnancy. *J Immunol* 191:145–153
- Schmidt E, Bastian B, Dummer R, Tony HP, Brocker EB, Zillikens D (1996) Detection of elevated levels of IL-4, IL-6, and IL-10 in blister fluid of bullous pemphigoid. *Arch Dermatol Res* 288:353–357
- Seki S, Osada S, Ono S, Aosasa S, Habu Y, Nishikage T, Mochizuki H, Hiraide H (1998) Role of liver NK cells and peritoneal macrophages in gamma interferon and interleukin-10 production in experimental bacterial peritonitis in mice. *Infect Immun* 66:5286–5294
- Sharma J, Balakrishnan L, Datta KK, Sahasrabudde NA, Khan AA, Sahu A, Singhal A, Getnet D, Raju R, Chatterjee A, Gowda H, Keshava Prasad TS, Shankar S, Pandey A (2015) A knowledgebase resource for interleukin-17 family mediated signaling. *J Cell Commun Signal*
- Spittler A, Schiller C, Willheim M, Tempfer C, Winkler S, Boltz-Nitulescu G (1995) IL-10 augments CD23 expression on U937 cells and down-regulates IL-4-driven CD23 expression on cultured human blood monocytes: effects of IL-10 and other cytokines on cell phenotype and phagocytosis. *Immunology* 85:311–317
- Subbannayya T, Balakrishnan L, Sudarshan G, Advani J, Kumar S, Mahmood R, Nair B, Sirdeshmukh R, Mukherjee KK, Umathe

- SN, Raju R, Prasad TSK (2013) An integrated map of corticotropin-releasing hormone signaling pathway. *J Cell Commun Signal* 4: 295–300
- Subbannayya Y, Anuja K, Advani J, Ojha UK, Nanjappa V, George B, Sonawane A, Kumar RV, Ramaswamy G, Pandey A, Somani BL, Raju R (2014) A network map of the gastrin signaling pathway. *J Cell Commun Signal* 8:165–170
- Tilg H, van Montfrans C, van den Ende A, Kaser A, van Deventer SJ, Schreiber S, Gregor M, Ludwiczek O, Rutgeerts P, Gasche C, Koningsberger JC, Abreu L, Kuhn I, Cohard M, LeBeaut A, Grint P, Weiss G (2002) Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. *Gut* 50:191–195
- van der Poll T, Jansen J, Levi M, ten Cate H, ten Cate JW, van Deventer SJ (1994) Regulation of interleukin 10 release by tumor necrosis factor in humans and chimpanzees. *J Exp Med* 180:1985–1988
- van Iersel MP, Kelder T, Pico AR, Hanspers K, Coort S, Conklin BR, Evelo C (2008) Presenting and exploring biological pathways with PathVisio. *BMC Bioinforma* 9:399
- Verbon A, Juffermans N, Van Deventer SJ, Speelman P, Van Deutekom H, Van Der Poll T (1999) Serum concentrations of cytokines in patients with active tuberculosis (TB) and after treatment. *Clin Exp Immunol* 115:110–113
- Wang P, Wu P, Siegel MI, Egan RW, Billah MM (1994) IL-10 inhibits transcription of cytokine genes in human peripheral blood mononuclear cells. *J Immunol* 153:811–816
- Windsor WT, Syto R, Tsarbopoulos A, Zhang R, Durkin J, Baldwin S, Paliwal S, Mui PW, Pramanik B, Trotta PP et al (1993) Disulfide bond assignments and secondary structure analysis of human and murine interleukin 10. *Biochemistry* 32:8807–8815
- Zdanov A (2010) Structural analysis of cytokines comprising the IL-10 family. *Cytokine Growth Factor Rev* 21:325–330
- Zhong J, Sharma J, Raju R, Palapetta SM, Prasad TS, Huang TC, Yoda A, Tyner JW, van Bodegom D, Weinstock DM, Ziegler SF, Pandey A (2014) TSLP signaling pathway map: a platform for analysis of TSLP-mediated signaling. *Database (Oxford)* 2014:bau007